Abstract
Purpose
To investigate the presence of a placebo dose–response effect in four randomized, double-blind, placebo-controlled, multi-dose hot flash clinical trials conducted at Mayo Clinic.
Methods
Hot flash score, frequency, and hot flash-related distress for each placebo dose level were summarized at each time point by mean and standard deviation and changes from baseline were plotted to visualize a possible placebo dose–effect response. Furthermore, a meta-analysis was conducted for each endpoint in the highest and lowest dosage arms across the four trials.
Results
Longitudinal plots of mean hot flash scores, frequencies, and hot flash-related distress scores in patients taking placebo in each study showed a decline in hot flash scores over time without any clinically meaningful differences between the lowest and highest dosage arms in each study. The meta-analysis for each endpoint in the highest and lowest dosage arms across the four trials revealed no clinically important differences either.
Conclusion
While the current study cannot rule out the existence of a placebo dose–response effect in multi-dose placebo-controlled trials in patients with hot flashes or other conditions, it suggests, along with the available data in the placebo literature, that, at least in well-conducted multi-dose clinical trials in which the placebo was used as control, such an effect, if it exists at all, should be very small. Therefore, pooling data from different placebo subgroups is unlikely to compromise the validity of comparisons between the combined placebo arms and each treatment arm.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Not applicable.
References
Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ (2000) Venlafaxine in the management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356(9247):2059–2063
Loprinzi CL, Dueck AC, Khoyratty BS, Barton DL, Jafar S, Rowland KM Jr, Atherton PJ, Marsa GW, Knutson WH, Bearden JD 3rd, Kottschade L, Fitch TR (2009) A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol 20(3):542–549
Park H, Qin R, Smith TJ, Atherton PJ, Barton DL, Sturtz K, Dakhil SR, Anderson DM, Flynn K, Puttabasavaiah S, Le-Lindqwister NA, Padula GD, Loprinzi CL (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22(6):627–632
Barton DL, LaVasseur BI, Sloan JA, Stawis AN, Flynn KA, Dyar M, Johnson DB, Atherton PJ, Diekmann B, Loprinzi CL (2010) Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 28(20):3278–3283
Leon-Ferre RA, Novotny PJ, Faubion SS, Ruddy KJ, Flora D, Dakhil C, Rowland KM, Graham ML, Le-Lindqwister N, Loprinzi CL (2020) A randomized double-blind placebo-controlled trial of oxybutynin (Oxy) for hot flashes ACCRU study SC-1603. JNCI cancer Spectrum 4(1):pkz088
Fleiss JL (1993) The statistical basis of meta-analysis. Stat Methods Med Res 2(2):121–145
Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129
de Craen AJM, Tijssen JGP, de Gens J, Kleijnen J (2000) Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebo. J Neurol 247:183–188
Kaptchuk TJ, Goldman P, Stone DA, Stason WB (2000) Do medical devices have enhanced placebo effects? J Clin Epidemiol 53:786–792
Kaptchuk TJ, Stason WB, Davis RB et al (2006) Sham device v inert pill: randomized controlled trial of two placebo treatments. BMJ 332:391–397
Linde K, Niemann K, Meissner K (2010) Are sham acupuncture interventions more effective than (other) placebos? A re-analysis of data from the Cochrane Review on Placebo Effects. Forsch Komplementarmedizin 17:259–264
Meissner K, Fassler M, Rucker G et al (2013) Differential effectiveness of placebo treatments A systematic review of migraine prophylaxis. JAMA Intern Med 173(21):1941–1951
Espay AJ, Norris MM, Eliassen JC et al (2015) Placebo effect of medication cost in Parkinson disease. Neurology 84(8):794–802
Hrobjartsson A, Goetzsche PC (2001) Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344:1594–1602
Vase L, Riley JL III, Price DD (2002) A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 99:443–452
Vase L, Petersen GL, Riley JL III, Price DD (2002) Factors contributing to large analgesic effects in placebo mechanism studies conducted between 2002 and 2007. Pain 145:36–44
Petersen GL, Finnerup NB, Nørskov KN et al (2012) Placebo manipulations reduce hyperalgesia in neuropathic pain. Pain 153(6):1292–1300
Kaptchuk TJ, Kelley JM, Conboy LA et al (2008) Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 336(7651):999–1003
Weimer K, Colloca L, Enck P (2015) Placebo effects in psychiatry: mediators and moderators. Lancet Psychiatry 2(3):246–257
Blackwell B, Bloomfield SS, Buncher CR (1972) Demonstration to medical students of placebo responses and non-drug factors. Lancet 7763:1279–1282
Gruber CM, King EP, Best MM et al (1955) Clinical bio-assay of oral analgesic activity of propoxyphene (Lilly), acetylsalicylic acid, and codeine phosphate, and observations on placebo reactions. Arch Int Pharmacodyn Ther 104(2):156–166
Gruber CM (1956) Interpreting medical data. Arch Intern Med 98:767–773
Rickels K, Hesbacker PT, Weise CC, Gray B, Feldman HS (1970) Pills and improvement: a study of placebo response in psychoneurotic outpatients. Psychopharmacologia 16:318–328
Samuels AS, Edison CB (1961) A study of the psychiatric effects of placebo. J Louisiana State Med Society 113:114–117
de Craen AJM, Moerman DE, Heisterkamp SH, Tygat GN, Tijssen JG, Kleijnen J (1999) Placebo effect in the treatment of duodenal ulcer. J Clin Pharmacol 48:853–860
Diener HC, Dowson AJ, Ferrari M, Nappi G, Tfelt-Hansen P (1999) Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials. Cephalalgia 19(8):699–700
Papakostas GI, Fava M (2009) Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19(1):34–40
Elsenbruch S, Enck P (2015) Placebo effects and their determinants in gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 12(8):472–485
Enck P, Klosterhalfen S (2019) Placebos and the placebo effect in drug trials. Handb Exp Pharmacol 260:399–431
Bardia A, Novotny P, Sloan J, Barton D, Loprinzi C (2009) Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause 16(3):477–483
Funding
Gateway for Cancer Research provided funding for this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
He, J., Perez, D.G., Le-Rademacher, J.L. et al. Does the placebo effect on hot flashes depend on the placebo dose?. Support Care Cancer 29, 6741–6749 (2021). https://doi.org/10.1007/s00520-021-06244-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-021-06244-3